Frankfurt
04.04.25
15:29 Uhr
2,940 Euro
-0,100
-3,29 %
-3,29 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Guggenheim cuts Nanobiotix stock target to $8, maintains buy | 2 | Investing.com | ||
| Mi | Nanobiotix GAAP EPS of -€1.44 | 1 | Seeking Alpha | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Mi | Nanobiotix S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| Mi | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results | 60 | GlobeNewswire (Europe) | Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and... ► Artikel lesen | |
| Mo | Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 | 1 | GlobeNewswire (USA) | ||
| 27.03. | Nanobiotix reports promising NSCLC treatment study results | 1 | Investing.com | ||
| 27.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Nanobiotix S.A.: Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC | 263 | GlobeNewswire (Europe) | Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of... ► Artikel lesen | |
| 18.03. | Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden | 3 | Benzinga.com | ||
| 18.03. | Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash | 13 | FierceBiotech | ||
| 17.03. | Nanobiotix S.A.: NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 | 111 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic... ► Artikel lesen | |
| 13.03. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 13.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.02. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 12.02. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.01. | Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study | 1 | Zacks | ||
| 21.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 21.01. | Nanobiotix S.A.: NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer | 178 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based... ► Artikel lesen | |
| 10.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,487 | +2,85 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,500 | +6,84 % | COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer | ||
| HALOZYME THERAPEUTICS | 54,00 | -0,92 % | Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 1,880 | -1,31 % | AbCellera Biologics Aktie: Die Falle schnappt zu? | AbCellera Biologics Inc. (ABCL) hat kürzlich Informationen zu seinen Forschungsinitiativen und finanziellen Ergebnissen veröffentlicht, die den laufenden Übergang zu einem Biotechnologieunternehmen... ► Artikel lesen | |
| GLOW LIFETECH | 0,048 | 0,00 % | Glow LifeTech Corp.: Glow Lifetech Triples Capacity via Automated Production Line as MOD Becomes #2 Oils SKU in Ontario | Toronto, Ontario--(Newsfile Corp. - March 25, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is accelerating its expansion with the acquisition of a... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 199,90 | -3,06 % | Should You Continue to Hold Bio-Rad Stock in Your Portfolio? | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,540 | -0,65 % | Whitehawk Therapeutics files to sell 41.67M shares of common stock for holders | ||
| MINERVA NEUROSCIENCES | 1,490 | +16,41 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates | BURLINGTON, Mass., Feb. 25, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,360 | -10,49 % | Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission | ||
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs CEO David Dodd erwirbt Stammaktien im Wert von 10.800 US-Dollar | ||
| OVID THERAPEUTICS | 0,238 | -9,16 % | Ovid Therapeutics Aktie: Rückschritte statt Erfolge? | Biopharma-Unternehmen kämpft mit Kursverlusten trotz gefüllter Kassen und vielversprechender Entwicklungen bei Medikamentenkandidaten für neurologische Erkrankungen Ovid Therapeutics hat kürzlich Updates... ► Artikel lesen | |
| COCRYSTAL | 1,300 | 0,00 % | Cocrystal Pharma, Inc. - 10-K, Annual Report | ||
| PRECISION BIOSCIENCES | 4,140 | -1,43 % | Precision BioSciences, Inc.: Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B | Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024
... ► Artikel lesen |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-3,29 %) liegt der Kurs bei 2,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.
